Law Offices of Thomas J. Lamb, P.A.

Law Offices of Thomas J. Lamb, P.A. Blogs

Blog Authors

Latest from Law Offices of Thomas J. Lamb, P.A.

Bladder Cancer Drug Padcev is Linked to Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in 2021   (Posted by Tom Lamb at Drug Injury Watch)   Padcev (enfortumab vedotin-ejfv), an injection drug for intravenous use, was approved by the FDA in December 2019 for the treatment of certain adult patients with locally advanced or metastatic urothelial cancer (mUC), a type of bladder cancer. It is important for patients and their families to know…
Two Recent Medical Articles on Vision Side Effects of Elmiron (pentosan polysulfate sodium, or PPS) for Interstitial Cystitis   (Posted by Tom Lamb at Drug Injury Watch)   Chronic use of Elmiron (pentosan polysulfate sodium, or PPS) for interstitial cystitis, also known as bladder pain syndrome, has been associated with maculopathy in patients. The mechanism for this link between Elmiron and maculopathy, however, is still not fully understood. And the diagnostic means for identifying…
JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Get Drug Label Changes and Drug Use Limitations in September 2021   (Posted by Tom Lamb at Drug Injury Watch)   On September 1, 2021, the FDA released this alerting news about the association of Xeljanz use with adverse events involving blood clots and death: The increased risk of blood clots and death has been linked to the lower dose of Xeljanz as well as the higher dose…
Consolidation of Tasigna Drug Injury Cases Involving Atherosclerosis-related Diseases and Medical Conditions   (Posted by Tom Lamb at Drug Injury Watch)   On August 12, 2021, the United States Judicial Panel on Multidistrict Litigation (JPML) created a new federal court multi-district litigation (MDL) matter for Novartis AG’s cancer drug Tasigna. This newly created Tasigna MDL involves Tasigna drug injury lawsuits filed against Novartis allege that Tasigna caused atherosclerosis-related diseases and subsequent Tasigna side effects…
We Point Out Some Resources From FDA and National Library of Medicine Which Will Get You Started   (Posted by Tom Lamb at Drug Injury Watch)   At the Law Offices of Thomas J. Lamb, we represent people in drug injury cases where there is a serious injury or death involving a prescription drug and the legal liability rests with a pharmaceutical company based on products liability law. When investigating relevant background facts for…
Drug Injury Lawsuits are Personal Injury or Wrongful Death Cases Involving a Serious Side Effect or a Severe Adverse Reaction   (Posted by Tom Lamb at Drug Injury Watch)   A drug injury lawsuit usually involves a personal injury case or wrongful death case filed on behalf of the person who experienced a serious side effect or a severe adverse reaction caused by a prescription drug. Some unsafe drugs have been the subject of…
Increased Risk for This New Vision/Eyes Side Effect Highest in Elderly Patients and Chronic Kidney Disease Patients   (Posted by Tom Lamb at Drug Injury Watch)   In June 2021 it was reported that Invokana, Farxiga, and Jardiance, as well as other drugs in the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors class, are associated with an increased risk of retinal vein occlusion. This new SGLT2 inhibitors side effect was the subject of a presentation at the…
Outside Experts Could Review All JAK Inhibitors Risk/Benefit Profiles as Regards Several Requested New Indications   (Posted by Tom Lamb at Drug Injury Watch)   A few months ago we wrote about a possible FDA Advisory Committee meeting for Xeljanz, Rinvoq, and other Janus kinase (JAK) inhibitors in this April 15, 2021 post, “Xeljanz and Other JAK Inhibitors: Drug Safety Concerns Indicated by Recent FDA Actions“. And recently the FDA delayed its…
For Patients with Polyester-based Polyurethane (PE-PUR) Exposures, Potential Health Risks Include Cancers and Organ Failures   (Posted by Tom Lamb at Drug Injury Watch)   In June 2021, the healthcare technology company Royal Philips issued a products recall for certain Philips Bi-Level PAP, CPAP, and Mechanical Ventilator devices due to possible toxic exposures from the polyester-based polyurethane (PE-PUR) sound abatement foam component in these Philips products.  From our perspective,  a few cancers and some…
New Jersey Tasigna Multi-county Litigation (MCL), Federal Court Tasigna Multidistrict Litigation (MDL)   (Posted by Tom Lamb at Drug Injury Watch)   In early June 2021, the New Jersey Supreme Court consolidated Tasigna drug injury lawsuits filed against Novartis Pharmaceuticals Corp. before one judge for pretrial proceedings as part of a New Jersey state court multi-county litigation (MCL). And in July 2021 the U.S. Judicial Panel on Multidistrict Litigation (JPML) is expected to hear…